Log In


Company Name : Laurus Labs Ltd.

Friday, May 19, 2017 3:45PM IST (10:15AM GMT)


Laurus Labs PAT Grows by 40%; Board Recommends a Dividend of 15%

Hyderabad, India

Laurus Labs Ltd. (Laurus), a leading R&D driven pharmaceutical company in India announces its Q4 & FY17 results.


FY17 Laurus reported:

  • Total Revenue rose 6.6% to Rs.18,919 mn as compared to Rs.17,746 mn
  • EBITDA higher by 19.3% at Rs.4,461 mn from Rs.3,740 mn
  • PAT increased 40.0% to Rs.2,026 mn from Rs.1,477 mn
  • EPS (Diluted) for the period stood at Rs.20 per share
  • The Board of Directors, at their meeting held on May 18, 2017, recommended a final dividend of Rs.1.50 per share, subject to the approval of shareholders.

Key Business Highlights



  • Prepayment of Loans resulted interest cost reduction apart from reduction in cost of funds
  • Capex investments in FY 17 Rs.3,155 million.
  • R & D opex investments Rs.1,050 million and 5.6% as percentage of sales in FY 17.
  • Unit IV expansion is in progress, the facility will add capacity to Generics API, Synthesis and Ingredients business.
  • Operations at Sriam (100% subsidiary of Laurus) Unit 2 started in FY 17.

Generic API

  • Laurus in partnership with Natco has launched Velpatasivir (Hep-C) product in India in May 2017.
  • As on Mar 17, the Company has filed 202 patent applications and 39 patents granted.
  • USFDA inspection scheduled in May 2017 for API facility.

Generic FDF

  • Filed 3 ANDAs and in addition completed 6 product validations in FY 17.
  • Capacity expansion of 5 billion tablets is in progress.
  • WHO inspection completed in March 2017.
  • FDF opex investments are Rs.982 million which includes Rs.335 million relating to the R& D in FY 17.
  • Company received EIR from USFDA for formulations unit 2.


  • Unit 5 (dedicated manufacturing facility for Aspen) has commenced validations in QE 31st Mar 17.


  • Received National Safety Award 2016 from Govt of India.
  • Received Best Management Award 2016 from Govt of AP.
  • Received Business Excellence Award 2017 from HMTV.
  • Dr. M. Venu Gopala Rao appointed as independent director and non-executive Chairman
  • Dr. Ravindranath Kancherla appointed as independent director
  • Mr. Krishna Chaitanya Chava son of Dr Satyanarayana Chava, CEO joined the Company as AVP Corporate Development in Apr 17.

BSE: 540222
ISIN - NE947Q01010





Click here for Media Contact Details
CONTACTS : Laurus Labs Ltd.Pavan Kumar N,+919246564666mediarelations@lauruslabs.comhttp://www.lauruslabs.com

More News from Laurus Labs Ltd.

19/05/2017 8:10PM

लॉरस लैब्स का कर के बाद लाभ (पीएटी) 40% बढ़ा; बोर्ड ने 15% के लाभांश की सिफारिश की

अनुसंधान और विकास आधारित भारत की अग्रणी फार्मास्यूटिकल कंपनी लॉरस लैब्स लिमिटेड (लॉरस) ने चौथी तिमाही और वित्त वर्ष 17 के अपने परिणामों की घोषणा की है।   विव17 लॉरस ने रिपोर्ट ...

14/02/2017 1:03PM

लॉरस लैब्स ने सफल आईपीओ के बाद पहले तिमाही परिणाम में तीसरी तिमाही के दौरान मज़बूत विकास का प्रदर्शन किया

अनुसंधान और विकास आधारित भारत की अग्रणी फार्मास्यूटिकल कंपनी लॉरस लैब्स लिमिटेड (लॉरस), ने वित्त वर्ष 17 के नौ महीने और तीसरी तिमाही के नतीजों की घोषणा की है। विव 17 के 9 महीनों के नतीजे : कुल ...

14/02/2017 12:36AM

Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India announces its 9M & Q3 FY17 results.   9M FY17 results:   Total Revenue grew by 9.7% to ...

Similar News

20/10/2017 2:30PM

उद्यमशीलता के लिए गोल्डमैन सैक्स ने किया आरएक्सएडवांस को सम्मानित

गोल्डमैन सैक्स (एनवाईएसई : जीएस) ने सैंटा बारबरा, कैलिफ़ोर्निया में अपने बिल्डर्स + इनोवेटर्स समिट में आरएक्सएडवांस के प्रेसिडेंट और सीईओ रवि इका को वर्ष 2017 के सर्वाधिक आकर्षक उद्यमी के रूप में सम्मानित ...

No Image

20/10/2017 1:46PM

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Celgene Corporation (NASDAQ:CELG) announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, in relapsing multiple ...